Evidence map›Paper›PMID 38769450›Full record

ArticleBritish journal of cancer2024

Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab.

Koen Zwart, Sietske C M W van Nassau, Frederieke H van der Baan, Miriam Koopman, Petur Snaebjornsson, Anna J van Gestel, Geraldine R Vink, Jeanine M L Roodhart

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Koen ZwartDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Sietske C M W van NassauDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Frederieke H van der BaanDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Miriam KoopmanDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0003-1550-1978
Petur SnaebjornssonDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-1086-8108
Anna J van GestelDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Geraldine R VinkDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Jeanine M L RoodhartDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. J.Roodhart@umcutrecht.nl.ORCID 0000-0003-1398-8970

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEncorafenib-cetuximab has been approved for pretreated BRAF

methodsThis population-based real-world study includes all mCRC patients in the Netherlands treated with encorafenib-cetuximab since approval. Individual patient data and pathology reports were collected. Overall survival (OS) was compared to BEACON and subgroup analyses were conducted for patients who would have been eligible and ineligible for BEACON.

results166 patients were included with a median follow-up time of 14.5 months. Median OS was 6.7 months (95% CI:6.0-8.3) and differed from BEACON (9.3 months; 95% CI:8.0-11.3, p-value 0.002). Thirty-six percent of real-world patients would have been ineligible for the BEACON trial. Trial ineligible subgroups with symptomatic brain metastases and WHO performance status ≥2 had the poorest median OS of 5.0 months (95% CI:4.0-NR) and 3.9 months (95% CI:2.4-NR).

conclusionThis real-world cohort of mCRC patients treated with encorafenib-cetuximab showed a clinically relevant efficacy-effectiveness gap for OS. The chance of survival benefit from encorafenib-cetuximab in patients with brain metastases and/or WHO performance status ≥2 is negligible as neither efficacy nor effectiveness has been demonstrated.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarbamatesCetuximabColorectal NeoplasmsMutationProto-Oncogene Proteins B-rafSulfonamidesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm MetastasisNetherlandsBRAF protein, humanCarbamatesCetuximabencorafenibProto-Oncogene Proteins B-rafSulfonamides

Identifiers

PMID38769450
PMCPMC11231318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.